Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine

BIOLOGICAL3 trials

Conditions

Advanced Head and Neck Squamous Cell CarcinomaAdvanced Squamous Non-Small Cell Lung CarcinomaChronic Obstructive Pulmonary DiseaseColo-rectal CancerLung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaPD-L1 PositivePneumonia

Early Phase 1

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

CompletedNCT04298606

Roswell Park Cancer InstituteChronic Obstructive Pulmonary Disease, Lung Non-Small Cell Carcinoma, Pneumonia +5

Start: 2021-11-22End: 2026-02-06Updated: 2026-03-17

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Active, not recruitingNCT06011772

Roswell Park Cancer InstituteColo-rectal Cancer

Start: 2023-12-18End: 2026-12-04Updated: 2026-03-11

Phase 1

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Active, not recruitingNCT02955290

Roswell Park Cancer InstituteAdvanced Head and Neck Squamous Cell Carcinoma, Advanced Squamous Non-Small Cell Lung Carcinoma, Lung Non-Small Cell Carcinoma +13

Start: 2016-12-22End: 2027-12-09Updated: 2025-11-07

Cancer Research2024-04-052 citations

Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2023-06-017 citations

Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non–small cell lung cancer patients.

Journal of Clinical Oncology2023-06-011 citations

Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer

Future Oncology2023-05-185 citations

Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine

Sponsors

Conditions

Early Phase 1

Phase 1

Related Papers